In a case series of non–small cell lung cancer (NSCLC) by Kitagawa et al., partial responses or stable disease were observed in some patients after rechallenge with an anti–PD-1 antibody following anti–PD-L1 antibody therapy, suggesting that this approach may be a viable treatment option in selected cases (21). The gene discussed is CD274; the disease is non-small cell lung carcinoma.